Favipiravir

About FUJIFILM Pharma

FUJIFILM Pharmaceuticals U.S.A., Inc., founded in 2004, is a U.S.-based subsidiary of FUJIFILM Corporation that operates a hybrid business model combining proprietary drug development with a specialized CDMO service. Its core technology platform centers on advanced drug delivery systems, including liposomes and LNPs, which it applies to its internal pipeline of oncology candidates and offers as a service to external partners. The company is advancing several clinical-stage assets, has a recently approved antiviral, and is positioned at the intersection of the growing precision medicine and advanced drug delivery markets.

About Viriom

Viriom is a clinical-stage biotech company advancing a pipeline of antiviral therapies, primarily for HIV, with a mission to ensure broad global access. Its lead asset, Elpida® (elsulfavirine), is an NNRTI approved in Russia and Eurasian markets, with development ongoing for weekly oral and long-acting injectable formulations. The company is also expanding its focus to include treatments for SARS-CoV-2, influenza, Hepatitis B/C, and solid tumors, supported by a leadership team with deep virology and drug development expertise.

Therapeutic Areas